APMONIA THERAPEUTICS
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.6Mattributed |
|---|---|
| Latest round | grant, $2.6M, 2024-07-15attributed |
| Founded | 2017 |
| Headquarters | Nancy, France |
| Industry | bio |
| Stage | unknown |
| Website | apmoniatherapeutics.com |
Apmonia Therapeutics develops peptide-based immunotherapies that disrupt the tumor micro-environment and stimulate immune response in solid tumors. It serves oncologists and patients with cancers where existing checkpoint inhibitors are ineffective. The TAX2 peptide-driven approach targets thrombospondin pathways that small-molecule and antibody oncology programs have largely left untouched.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-15 | grant | $2.6M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | apmoniatherapeutics.com, read 2026-05-08 |
| Description | self-reported | apmoniatherapeutics.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.